FDA Approves Changes to REMS Program : vimarsana.com

The FDA approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy, REMS, Program. The FDA’s approval of commercial dispensing of mifepristone likely will not change the current practice of prescribing and dispensing mifepristone for abortion.

Related Keywords

Maryland , United States , American , , Jackson Women Health Organization , Drug Administration , Maryland Us District Court , Us Supreme Court , American College Of Obstetricians , American Civil Liberties Union , Program Modifications , Mitigation Strategy Program , Program For Mifeprex , Mifepristone Risk Evaluation , Mitigation Strategy , Mifepristone Tablets , American College , Health Organization , Prescriber Agreement Form , Pharmacy Agreement Form , Medication Guide , Patient Agreement Form , Summary Review , Medical Termination , Pregnancy Through Ten Weeks Gestation , Risk Evaluation , Mitigation Strategies , Approving Mifepristone , Legal , Business , Government , Fda , Food And Drug Administration , Ifepristone Risk Evaluation And Mitigation Strategy Program , Rems Program , Cogv Fda , N Person Dispensing Requirement , Dobbsv Jackson Womens Health Organization , Mifeprex , Abortion Access , Edications That Cause Abortion ,